Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The reactivation of wild-type p53 could potentially improve the treatment of many cancer patients. One strategy to achieve this is to target the p53 regulators MDM2 and MDMX. This Review discusses our understanding of how these proteins regulate p53 and the progress that has been made in targeting them.
